AAN 2022 and Trial Updates View overview page

8:29
Losmapimod as a potential treatment for facioscapulohumeral muscular dystrophy (FSHD)
Christopher Morabito • 11 Apr 2022
4:12
COVID-19 and post-acute neurological sequelae
Jennifer Frontera • 3 Apr 2022
5:14
Alternatives in HD treatment: RNA interference, small molecules, and combination approaches
Jee Bang • 4 Apr 2022
1:12
The CHIMES trial: disease activity & biomarkers in minority patients treated with ocrelizumab
Lilyana Amezcua • 4 Apr 2022
1:52
Relapse rate from the ULTIMATE studies of ublituximab for relapsing MS
Lawrence Steinman • 11 Apr 2022
2:42
EMTICS: The role of gene-environment interactions in the development of tics in pediatric patients
Davide Martino • 3 Apr 2022
1:51
Phase II extension trial of CNM-Au8 in ALS
Matthew Kiernan • 4 Apr 2022
1:49
The pipeline of late-stage therapeutic options for patients with ALS
Matthew Kiernan • 4 Apr 2022
3:10
Direct oral anticoagulants after stroke: ongoing clinical trials
Edip Gurol • 2 Apr 2022
1:58
AZ257: Novel dopamine transporter receptor for the treatment of MS
Mirla Avila • 12 Apr 2022
3:03
Vaginal estriol improves quality of life for patients with relapsing/remitting multiple sclerosis
Mirla Avila • 12 Apr 2022
6:23
Rehabilitation combined with excitatory transcranial magnetic stimulation for patients with MS
Letizia Leocani • 4 Apr 2022
0:38
Assessing remibrutinib in patients with relapsing MS
Xavier Montalban • 4 Apr 2022
5:06
MONEAD: the effects of antiseizure medications on breastfeeding infants
Kimford Meador • 31 Mar 2022
4:27
AOC programs in development for DMD and myotonic dystrophy
Arthur Levin • 6 Apr 2022
2:52
Complement inhibitor therapy for myasthenia gravis: current and future outlooks
James F. Howard Jr. • 12 Apr 2022
The content of VJNeurology is intended for healthcare professionals